Results 231 to 240 of about 111,544,121 (255)
ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma +8 more
wiley +1 more source
ABSTRACT Background Real‐world data after percutaneous coronary intervention (PCI) using drug‐coated balloons (DCBs) in acute coronary syndrome (ACS) are limited. Aims We compared 1‐year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non‐ACS patients.
Takashi Muramatsu +18 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Diabetes and Cancer: A Consensus Report†‡§¶‖
Ca-A Cancer Journal for Clinicians, 2010Susan M. Gapstur +2 more
exaly
Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage
Circulation, 2014John W. McEvoy, Elizabeth Selvin
exaly

